Previous 10 | Next 10 |
Planning for a December 2023 U.S. launch for H. pylori , together with the U.S. launch of vonoprazan for Erosive GERD, if approved FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on develop...
2023-10-05 12:43:14 ET Summary Phathom Pharmaceuticals is a small biopharma firm focused on developing treatments for gastrointestinal diseases. The company has recently filed some marketing applications around its primary drug candidate. The company ended the second quarter w...
2023-09-26 12:25:14 ET More on Phathom Pharmaceuticals Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals Historical earnings data for Phathom Pharmaceuticals Financial information for Phathom Pharmaceuticals Phathom Pharma: Time To Take Profits (...
Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile consistent with prior vonoprazan studies New drug application (NDA) seeks U.S. Food and Drug Ad...
2023-08-21 09:48:10 ET More on Phathom Pharmaceuticals Phathom Pharma: Time To Take Profits (Rating Downgrade) Phathom resubmits vonoprazan application for esophagitis to FDA, announces stock offering Phathom gains as Evercore ISI upgrades on potential vonoprazan app...
Six-month stability data remain more than 10x below the acceptable intake limit set by the U.S. Food and Drug Administration (FDA) and continue to support the requested product shelf life Submission of six-month stability data satisfies Phathom's stability data submission requirements for...
2023-08-10 12:23:37 ET Phathom Pharmaceuticals press release ( NASDAQ: PHAT ): Q2 GAAP EPS of -$0.84 beats by $0.14 . As of June 30, 2023, cash and cash equivalents were $248.8 million. For further details see: Phathom Pharmaceuticals GAAP EPS of -$0.84 beats...
Prior Approval Supplement (PAS) for VOQUEZNA ® TRIPLE PAK ® and VOQUEZNA ® DUAL PAK ® assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 30, 2023 by the U.S. Food and Drug Administration (FDA) U.S. commercial launch for H. pylori ...
2023-08-07 14:34:09 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the safest sectors on the market is biotech. After all, we can’t stop people from aging — at least not yet. We have millions of people retiring and demanding better care. T...
2023-07-14 16:12:22 ET Summary Phathom Pharmaceuticals, Inc. is trading near 52-week highs. Despite its potential, there are reasons, like a competitive market, why we should take profits on Phathom Pharmaceuticals. If it falls back without major negative reasons before approv...
News, Short Squeeze, Breakout and More Instantly...
Phathom Pharmaceuticals Inc. Company Name:
PHAT Stock Symbol:
NYSE Market:
2024-06-23 22:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...